Physician profile
Devicka D Persaud
NPI 1801965371
$24,548.17
in general payments reported to CMS, 2019-2025
48 companies · $4,903 in 2025
The $4,903 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,929 · 2020: $1,608 · 2021: $2,895 · 2022: $2,606 · 2023: $4,490 · 2024: $6,117 · 2025: $4,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,409.80 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,397.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,153.36 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $1,263.55 | 2022-2025 | |
| Cequr Corporation | $1,237.61 | 2023-2025 | Cequr Simplicity |
| Biohaven Pharmaceuticals, INC. | $1,235.60 | 2021 | |
| Amgen INC. | $1,213.12 | 2023-2025 | Repatha, Tepezza, Repatha |
| Glaxosmithkline, LLC. | $1,192.73 | 2019-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Merck Sharp & Dohme LLC | $1,173.27 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Mannkind Corporation | $1,153.84 | 2019-2025 | Afrezza |
| Abbott Laboratories | $1,021.70 | 2020-2025 | Aveir, Gallant, Freestyle Libre 2 |
| Lilly USA, LLC | $738.92 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $716.80 | 2019-2025 | |
| Novo Nordisk INC | $700.31 | 2019-2025 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $623.87 | 2021-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $488.94 | 2024-2025 | Korlym |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $480.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $474.21 | 2019-2022 | |
| Astellas Pharma US INC | $461.28 | 2023-2025 | Veozah |
| Intuity Medical INC | $447.00 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Dexcom, INC. | $440.71 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Exact Sciences Corporation | $405.03 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $385.14 | 2024-2025 | Zoryve |
| Shockwave Medical, INC | $356.75 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $326.79 | 2020-2024 | |
| Aurinia Pharma U.S., INC. | $245.32 | 2022-2023 | Lupkynis |
| Beta Bionics, INC. | $229.97 | 2024 | Ilet Bionic Pancreas |
| Zealand Pharma US, INC. | $192.35 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $175.06 | 2025 | |
| Abbvie INC. | $173.21 | 2021-2024 | |
| Shield Therapeutics INC | $167.52 | 2023-2025 | Accrufer |
| Medtronic, INC. | $158.75 | 2021-2025 | Closurefast, Minimed 780g |
| Valeritas, INC. | $140.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $131.91 | 2022-2023 | |
| Ibsa Pharma INC. | $106.52 | 2021-2023 | Tirosint, Licart |
| Global Blood Therapeutics, INC. | $97.58 | 2020-2021 | |
| Esperion Therapeutics, INC. | $97.22 | 2020-2022 | |
| Allergan, INC. | $86.41 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $83.89 | 2022 | |
| Boston Scientific Corporation | $82.31 | 2025 | Avvigo Guidance System |
| Genzyme Corporation | $79.55 | 2024 | |
| Sumitomo Pharma America, INC. | $44.67 | 2025 | Gemtesa, Myfembree |
| Medtronic Minimed, INC. | $40.52 | 2020 | |
| Phathom Pharmaceuticals, INC. | $28.54 | 2024 | Voquezna |
| Scynexis, INC. | $24.29 | 2022 | |
| Genentech USA, INC. | $21.05 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $19.16 | 2022 | |
| Phadia US INC. | $18.41 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devicka Persaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.